indantadol
Indantadol is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2006 (NCT00375960)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glutamate [NMDA] receptorANTAGONIST
Glutamate [NMDA] receptor antagonist
- Glutamate receptor ionotropic, NMDA 1 (GRIN1) ↗
- Glutamate receptor ionotropic, NMDA 2A (GRIN2A) ↗
- Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ↗
- Glutamate receptor ionotropic, NMDA 2D (GRIN2D) ↗
- Glutamate receptor ionotropic, NMDA 3B (GRIN3B) ↗
- Glutamate receptor ionotropic, NMDA 2C (GRIN2C) ↗
- Glutamate receptor ionotropic, NMDA 3A (GRIN3A) ↗
- Glutamate (NMDA) receptor subunit zeta 1
- Glutamate [NMDA] receptor subunit epsilon 1
- Glutamate [NMDA] receptor subunit epsilon 2
- Glutamate [NMDA] receptor subunit 3A
- Glutamate [NMDA] receptor subunit epsilon 4
- Glutamate [NMDA] receptor subunit epsilon 3
- Glutamate NMDA receptor; GRIN1/GRIN2B
- Glutamate NMDA receptor; GRIN1/GRIN2A
- Ionotropic glutamate receptor NMDA 1/2C
- Ionotropic glutamate receptor NMDA 1/2D
- Glutamate NMDA receptor; GRIN1/GRIN2A/GRIN2B
- Glutamate receptor ionotropic, NMDA 1/2C/3B
- Monoamine oxidase AINHIBITOR
MAOA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIndantadol ↗
- ChEMBLCHEMBL3707400 ↗
Also known as
- chf 3381
- chf-3381
- chf-3381
- indantadol
- indantadol
- indantadol
- indantadol
- indantadol
- n-(2-indanyl)glycinamide
- n-(2-indanyl)glycinamide hydrochloride
- v3381
- v3381
- v3381
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01401673 | Phase 2 | Oct 1, 2009 | University of Manchester, Vernalis |
| NCT00794430 | Phase 2 | Dec 1, 2008 | Harvard University, Vernalis |
| NCT00375960 | Phase 2 | Jun 1, 2006 | Cita NeuroPharmaceuticals, Harvard University, Vernalis |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vernalis | For profit | 3 | 3 | 1 | 2006 |
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2006 |
| Cita NeuroPharmaceuticals | For profit | 1 | 0 | 1 | 2006 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2009 |